Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 235

1.

Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.

Sabo JP, Kort J, Ballow C, Haschke M, Battegay M, Fuhr R, Girlich B, Schobelock M, Feifel U, Lang B, Li Y, Elgadi M.

Clin Infect Dis. 2014 Nov 15;59(10):1420-8. doi: 10.1093/cid/ciu616. Epub 2014 Aug 4.

PMID:
25091302
2.

Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.

Bifano M, Hwang C, Oosterhuis B, Hartstra J, Grasela D, Tiessen R, Velinova-Donga M, Kandoussi H, Sevinsky H, Bertz R.

Antivir Ther. 2013;18(7):931-40. doi: 10.3851/IMP2674. Epub 2013 Aug 20.

PMID:
23963204
3.

The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.

Garvey L, Latch N, Erlwein OW, Mackie NE, Walsh J, Scullard G, McClure MO, Dickinson L, Back D, Winston A.

Antivir Ther. 2010;15(2):213-8. doi: 10.3851/IMP1517.

PMID:
20386076
4.

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.

Le Tiec C, Barrail A, Goujard C, Taburet AM.

Clin Pharmacokinet. 2005;44(10):1035-50. Review.

PMID:
16176117
5.

Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.

Hulskotte EG, Feng HP, Xuan F, van Zutven MG, Treitel MA, Hughes EA, O'Mara E, Youngberg SP, Wagner JA, Butterton JR.

Clin Infect Dis. 2013 Mar;56(5):718-26. doi: 10.1093/cid/cis968. Epub 2012 Nov 15.

PMID:
23155151
6.

Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.

King JR, Yogev R, Jean-Philippe P, Graham B, Wiznia A, Britto P, Carey V, Hazra R, Acosta EP; P1058 Protocol Team.

Antimicrob Agents Chemother. 2011 Sep;55(9):4290-4. doi: 10.1128/AAC.01334-10. Epub 2011 Jun 13.

7.

Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.

Calza L, Danese I, Colangeli V, Manfredi R, Magistrelli E, Verucchi G, Conti M, Motta R, Viale P.

Infect Dis (Lond). 2015 Sep;47(9):625-36. doi: 10.3109/23744235.2015.1034169. Epub 2015 Apr 15.

PMID:
25875396
9.

Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.

Khatri A, Dutta S, Wang H, Podsadecki T, Trinh R, Awni W, Menon R.

Clin Infect Dis. 2016 Apr 15;62(8):972-9. doi: 10.1093/cid/civ1213. Epub 2016 Jan 5.

PMID:
26740513
10.

Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers.

Joseph D, Rose P, Strelkowa N, Schultz A, Garcia J, Elgadi M, Huang F.

J Clin Pharmacol. 2015 Apr;55(4):384-91. doi: 10.1002/jcph.418. Epub 2014 Dec 8.

PMID:
25352040
11.

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.

Taburet AM, Piketty C, Chazallon C, Vincent I, Gérard L, Calvez V, Clavel F, Aboulker JP, Girard PM.

Antimicrob Agents Chemother. 2004 Jun;48(6):2091-6.

12.

Review of drug interactions with telaprevir and antiretrovirals.

van Heeswijk RP, Beumont M, Kauffman RS, Garg V.

Antivir Ther. 2013;18(4):553-60. doi: 10.3851/IMP2527. Epub 2013 Jan 23. Review.

PMID:
23344266
13.
14.

Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.

Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR, Harris DR, Havens PL; Adolescent Trials Network for HIV/AIDS Interventions.

Antimicrob Agents Chemother. 2008 Feb;52(2):631-7. Epub 2007 Nov 19.

15.

Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.

Dailly E, Tribut O, Tattevin P, Arvieux C, Perré P, Raffi F, Jolliet P.

Eur J Clin Pharmacol. 2006 Jul;62(7):523-6. Epub 2006 Jun 9.

PMID:
16763827
16.

Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteers.

Soon GH, Shen P, Yong EL, Pham P, Flexner C, Lee L.

Antimicrob Agents Chemother. 2010 Jul;54(7):2775-80. doi: 10.1128/AAC.01564-09. Epub 2010 Apr 12.

17.

Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.

DeJesus E, Lalezari JP, Osiyemi OO, Ruane PJ, Ryan R, Kakuda TN, Witek J.

Antivir Ther. 2010;15(5):711-20. doi: 10.3851/IMP1562.

PMID:
20710052
18.
19.

Lack of a significant drug interaction between raltegravir and tenofovir.

Wenning LA, Friedman EJ, Kost JT, Breidinger SA, Stek JE, Lasseter KC, Gottesdiener KM, Chen J, Teppler H, Wagner JA, Stone JA, Iwamoto M.

Antimicrob Agents Chemother. 2008 Sep;52(9):3253-8. doi: 10.1128/AAC.00005-08. Epub 2008 Jul 14.

20.

Supplemental Content

Support Center